Shares of XOMA Corporation (NASDAQ:XOMA) reached a new 52-week high on Thursday . The stock traded as high as $33.19 and last traded at $29.35, with a volume of 156700 shares changing hands. The stock had previously closed at $29.23.

Several analysts have weighed in on XOMA shares. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of XOMA in a research report on Thursday, August 10th. Zacks Investment Research raised XOMA from a “sell” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Tuesday, October 17th. TheStreet raised XOMA from an “e+” rating to a “c-” rating in a research report on Wednesday, November 29th. Finally, Wedbush reaffirmed a “hold” rating on shares of XOMA in a research report on Monday, August 14th. One analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $30.00.

The company has a quick ratio of 3.45, a current ratio of 3.45 and a debt-to-equity ratio of 3.53.

In other news, CEO James R. Neal sold 46,296 shares of XOMA stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $28.24, for a total transaction of $1,307,399.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Thomas M. Burns sold 6,983 shares of XOMA stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $30.99, for a total transaction of $216,403.17. Following the transaction, the chief financial officer now owns 13,538 shares of the company’s stock, valued at $419,542.62. The disclosure for this sale can be found here. Insiders have sold 87,069 shares of company stock valued at $2,517,993 over the last quarter. Company insiders own 3.02% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. California Public Employees Retirement System lifted its holdings in shares of XOMA by 95.5% during the first quarter. California Public Employees Retirement System now owns 21,780 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 10,640 shares during the last quarter. OxFORD Asset Management LLP purchased a new position in shares of XOMA during the third quarter valued at approximately $543,000. Finally, EAM Investors LLC purchased a new position in XOMA in the 3rd quarter worth approximately $835,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

TRADEMARK VIOLATION WARNING: “XOMA (XOMA) Sets New 12-Month High at $33.19” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/12/07/xoma-xoma-sets-new-12-month-high-at-33-19.html.

About XOMA

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.